Mucosal Melanoma Clinical Trials

7 recruiting

Mucosal Melanoma Trials at a Glance

14 actively recruiting trials for mucosal melanoma are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in St Louis, Battle Creek, and Anaconda. Lead sponsors running mucosal melanoma studies include Emory University, Fred Hutchinson Cancer Center, and Alpha-9 Oncology USA Inc..

Browse mucosal melanoma trials by phase

Treatments under study

About Mucosal Melanoma Clinical Trials

Looking for clinical trials for Mucosal Melanoma? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mucosal Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mucosal Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recurrent Mucosal MelanomaMucosal MelanomaAnal Melanoma+14 more
National Cancer Institute (NCI)101 enrolled147 locationsNCT05111574
Recruiting
Phase 1

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Melanoma+7 more
M.D. Anderson Cancer Center75 enrolled1 locationNCT03025256
Recruiting

Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study

Locally Advanced Merkel Cell CarcinomaLocally Advanced Mucosal MelanomaClinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8+5 more
Ohio State University Comprehensive Cancer Center70 enrolled1 locationNCT07215988
Recruiting
Phase 1

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

Melanoma MetastaticMucosal MelanomaUveal Melanoma, Metastatic
Alpha-9 Oncology USA Inc.50 enrolled4 locationsNCT07076550
Recruiting
Phase 1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell Carcinoma+22 more
Fred Hutchinson Cancer Center25 enrolled1 locationNCT05098210
Recruiting
Phase 2

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

Cutaneous MelanomaMucosal Melanoma
Melanoma Institute Australia494 enrolled1 locationNCT06999980
Recruiting
Phase 2

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Mucosal Melanoma
Memorial Sloan Kettering Cancer Center20 enrolled2 locationsNCT05384496
Recruiting
Phase 2

Neo-adjuvant Immunotherapy in Patients With Localized Melanoma

Mucosal MelanomaCutaneous Melanoma, Stage III
UNICANCER50 enrolled1 locationNCT07230613
Recruiting
Phase 2

Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery

Mucosal MelanomaPD-L1 Positive
The First Hospital of Jilin University220 enrolled1 locationNCT07400302
Recruiting
Phase 2

Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma

Resectable Mucosal Melanoma
Sun Yat-sen University32 enrolled1 locationNCT07336979
Recruiting
Phase 2

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

Cutaneous MelanomaMelanoma Stage IVMucosal Melanoma
University Health Network, Toronto54 enrolled1 locationNCT06319196
Recruiting
Phase 2

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

Mucosal Melanoma of the Head and Neck
Washington University School of Medicine19 enrolled1 locationNCT04318717
Recruiting
Phase 2

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Acral MelanomaMetastatic Cutaneous Melanoma+7 more
Emory University99 enrolled2 locationsNCT07155317
Recruiting
Phase 2

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8+4 more
SWOG Cancer Research Network112 enrolled331 locationsNCT04511013